Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.62 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756333 | 1.00 | DGAT1 (0.62) | DGAT1CSGALNACT1THRBCDK8KDR | |
| SCHEMBL1756233 | 0.91 | DGAT1 (0.64) | DGAT1 | |
| SCHEMBL1756236 | 0.91 | DGAT1 (0.64) | DGAT1 | |
| SCHEMBL1756224 | 0.90 | DGAT1 (0.75) | DGAT1CSGALNACT1 | |
| SCHEMBL1756229 | 0.90 | DGAT1 (0.75) | DGAT1CSGALNACT1 | |
| SCHEMBL1756319 | 0.87 | DGAT1 (0.64) | DGAT1CSGALNACT1 | |
| SCHEMBL1756318 | 0.87 | DGAT1 (0.64) | DGAT1CSGALNACT1 | |
| SCHEMBL1756239 | 0.86 | DGAT1 (0.83) | DGAT1CSGALNACT1CDK8KDRKIT | |
| SCHEMBL1756282 | 0.86 | DGAT1 (0.83) | DGAT1CSGALNACT1KDRKITTEK | |
| SCHEMBL1756270 | 0.84 | MEN1 (0.56) | DGAT1CSGALNACT1THRBKDRROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | disclosed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | DGAT1, DGAT2, DLAT | DGAT1 1/4885CSGALNACT1 555/4885THRB 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.